Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
1.220
0.00 (0.00%)
May 9, 2025, 3:16 PM - Market open
Nexalin Technology Revenue
In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth. Nexalin Technology had revenue of $27.18K in the quarter ending December 31, 2024, with 32.35% growth.
Revenue (ttm)
$168.72K
Revenue Growth
+52.35%
P/S Ratio
66.64
Revenue / Employee
$28,120
Employees
6
Market Cap
16.23M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NXL News
- 3 days ago - Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - GlobeNewsWire
- 4 days ago - Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewsWire
- 8 days ago - Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback - GlobeNewsWire
- 15 days ago - Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewsWire
- 16 days ago - Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management - GlobeNewsWire
- 18 days ago - Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices - GlobeNewsWire
- 25 days ago - Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - GlobeNewsWire
- 5 weeks ago - Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - GlobeNewsWire